Approaches to relapse after allogeneic stem cell transplantation

Current Opinion in Oncology

Volumn 23, Issue 2, 2011, Pages 203-208

  Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

adaptive immune therapy; allogeneic stem cell transplantation; donor lymphocyte infusion; molecular target therapy; relapse

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; AZACITIDINE; BLINATUMOMAB; BORTEZOMIB; CANCER VACCINE; CLOFARABINE; IMMUNOMODULATING AGENT; LENALIDOMIDE; MONOCLONAL ANTIBODY; NELARABINE; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SORAFENIB; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG RESPONSE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; NATURAL KILLER CELL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VACCINATION;

HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; RECURRENCE;

EID: 79952003666     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328342c6c8     Document Type: Article

References (59)

1. Bishop MR, Alyea EP 3rd, Cairo MS, et al. Introduction to the reports from the National Cancer Institute First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16:563-564.
2. Miller JS, Warren EH, van den Brink MR, et al. NCI First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biology underlying recurrence of malignant disease following allogeneic HSCT: graft-versus-tumor/leukemia reaction. Biol Blood Marrow Transplant 2010; 16:565-586.
3. Cairo MS, Jordan CT, Maley CC, et al. NCI First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant 2010; 16:709-728.
4. Alyea EP, DeAngelo DJ, Moldrem J, et al. NCI First International Workshop on the biology, prevention and treatment of relapse after allogeneic hematopoietic cell transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2010; 16:1037-1069.
5. Pavletic SZ, Kumar S, Mohty M, et al. NCI First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the epidemiology and natural history of relapse following allogeneic cell transplantation. Biol Blood Marrow Transplant 2010; 16:871-890.
6. Krö ger N, Bacher U, Bader P, et al. NCI First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant 2010; 16:1187-1211.
7. Krö ger N, Bacher U, Bader P, et al. NCI First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. Part II: Chronic leukemias, myeloproliferative neoplasms and lymphoid malignancies. Biol Blood Marrow Transplant 2010; 16:1325-1346.
8. Porter DL, Alyea EP, Antin JH, et al. NCI First International Workshop on the biology, prevention and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on treatment of relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16:1467-1503.
9. Shaw BE, Russell NH. Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. Bone Marrow Transplant 2008; 41:495-503. (Pubitemid 351386714)
10. Van Besien KW, de Lima M, Giralt SA, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versuslymphoma effects. Bone Marrow Transplant 1997; 19:977-982. (Pubitemid 27232173)
11. Kolb HJ, Mittermü ller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76:2462-2465.
12. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graftversus- leukemia responses from graft-versus-host disease. Blood 1995; 86:1261-1268.
13. Guglielmi C, Arcese W, Dazzi F, et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100:397-405. (Pubitemid 34761099)
14. Dazzi F, Szydlo RM, Cross NC, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96:2712-2716.
15. Oran B, Giralt S, Couriel D, et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 2007; 21:2540-2544. (Pubitemid 350148900)
16. Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 41:483-493. (Pubitemid 351386713)
17. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow-grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86:2041-2050.
18. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in .140. patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15:433-444. (Pubitemid 27074209)
19. Collins RH Jr, Goldstein S, Giralt S, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000; 26:511-516.
20. Cardoso AA, Schultze JL, Boussiotis VA, et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 1996; 88: 41-48. (Pubitemid 26230669)
21. Grigg A, Ritchie D. Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant 2004; 10:579-590. (Pubitemid 39157825)
22. Lokhorst HM, Wu K, Verdonck LF, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103:4362-4364. (Pubitemid 38685385)
23. Ayuk F, Shimoni A, Nagler A, et al. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 2004; 18:659-662. (Pubitemid 38425889)
24. Van de Donk NW, Kroger N, Hegenbart U, et al. Prognostic factors for donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006; 37:1135-1141. (Pubitemid 43871524)
25. 8 T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 2002; 8:625-632. (Pubitemid 35446754)
26. Mielcarek M, Storer BE, Flower MED, et al. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13:1160-1168. (Pubitemid 47413010)
27. Mortimer J, Blinder MA, Schulman S, et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol 1989; 7:50-57. (Pubitemid 19089081)
28. Levine JE, Braun T, Penza SL, et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20:405-412. (Pubitemid 34072522)
29. Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007; 25:4938-4945. (Pubitemid 350225492)
30. Eapen M, Giralt SA, Horowitz MM, et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004; 34:721-727. (Pubitemid 39406056)
31. Bosi A, Laszlo D, Labopin M, et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001; 19:3675-3684. (Pubitemid 32786280)
32. Kishi K, Takahashi S, Gondo H, et al. Second allogeneic bone marrow transplantation for posttransplant leukemia relapse: results of a survey of 66. cases in 24 Japanese institutes. Bone Marrow Transplant 1997; 19:461-466. (Pubitemid 27102012)
33. Jabbour E, Giralt S, Kantarjian H, et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009; 115:1899-1905.
34. Lubbert M, Bertz H, Wasch R, et al. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant 2009; 45:627-632.
35. De Padua SL, de Lima M, Kantarjian H, et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 2009; 43:839-843.
36. Czibere A, Bruns I, Krö ger N, et al. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 2010; 45:872-876.
37. Wassmann B, Pfeifer H, Stadler M, et al. Early molecular response to posttransplantation imatinib determines outcome in MRD\+ Philadelphiapositive acute lymphoblastic leukemia (Ph\+ ALL). Blood 2005; 106:458-463. (Pubitemid 40981238)
38. Tiribelli M, Sperotto A, Candoni A, et al. Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph\+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leuk Res 2009; 33:174-177.
39. Hayat A, McCann SR, Langabeer S, et al. Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation. Haematol 2009; 94:296-298.
40. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009; 113:6567-6571.
41. Milojkovic D, Mijovic A, Taylor CG, et al. Rituximab salvage following relapse after allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Br J Haematol 2000; 110:1013-1014.
42. 8 cytotoxic T cells. Leukemia 2001; 15:1619-1626. (Pubitemid 32994682)
43. Ratanatharathorn V, Pavletic S, Uberti JP. Clinical applications of rituximab in allogeneic stem cell transplantation: antitumor and immunomodulatory effects. Cancer Treat Rev 2009; 35:653-661.
44. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974-977.
45. Platzbecker U, Mohr B, von Bonin M, et al. Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative.CMML-2. and del(5q) not involving the EGR1 locus. Leukemia 2007; 21:2384-2385.
46. List A, Dewald G, Bennett J, et al., Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355:1456-1465. (Pubitemid 44511560)
47. Kröger N, Shimoni A, Zagrivnaja M, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004; 104:3361-3363. (Pubitemid 39507159)
48. Lioznov M, El-Cheikh J Jr, Hoffmann F, et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(\+)) and T (HLA-DR(\+)) cells. Bone Marrow Transplant 2010; 45:349-353.
49. Van de Donk NW, Kroger N, Hegenbart U, et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006; 107:3415-3416.
50. Sun K, Welniak LA, Panoskaltsis-Mortari A, et al. Inhibition of acute graft-versushost disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004; 101:8120-8125. (Pubitemid 38698064)
51. El-Cheikh J, Michallet M, Nagler A, et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematology 2008; 93:455-458. (Pubitemid 351398650)
52. Krö ger N, Zabelina T, Ayuk F, et al Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 2006 34, 770-775. (Pubitemid 43737100)
53. Byrne JL, Carter GI, Bienz N, et al. Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma. Bone Marrow Transplant 1998; 22:639-643. (Pubitemid 28486361)
54. Molldrem JJ, Komanduri K, Wieder E. Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions. Curr Opin Hematol 2002; 9:503-508. (Pubitemid 35191119)
55. Brauer KM, Werth D, von Schwarzenberg K, et al. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res 2007; 67:5489-5497. (Pubitemid 46997290)
56. Neelapu SS, Munshi NC, Jagannath S, et al. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant 2005; 36:315-323. (Pubitemid 41195164)
57. Falkenburg JH, Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemiareactive cytotoxic T lymphocytes. Blood 1999; 94:1201-1208. (Pubitemid 29380400)
58. Warren EH, Fujii N, Akatsuka Y, et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 2010; 115:3869-3878.
59. Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B- lineage leukemia effect. Blood 2003; 101:1637-1644. (Pubitemid 36182545)